About the project
The SteatoComp project's objective is to evaluate the relationship between obesity, diabetes and liver damage. The project targets three aspects: 1) the current epidemiological situation and characteristics of HCC occurred in patients with non-alcoholic fatty liver disease (NAFLD) and / or non-alcoholic steatohepatitis (NASH); 2) the impact characteristics of metabolic syndrome and NAFLD / NASH histologically diagnosed on clinical progression of chronic hepatitis B and C; 3) Optimization and validation of non-invasive diagnostic algorithms of non-alcoholic severe statohepatitis in patients at risk for NAFLD.
The clinical research will be conducted prospectively in a single academic center, respectively Clinic of Internal Medicine and Nephrology Fundeni, University of Medicine and Pharmacy "Carol Davila" Bucharest. The first and third objective results will be compared with those collected in the European register of hepatocellular carcinoma occurred in patients with NASH and those of multinational prospective cohort of patients with steatosis, metabolic risk factors and NAFLD histologically documented. These cohorts are currently being developed within the European Consortium funded by the FP7 program called FLIP (inhibitor progression of fatty liver), coordinated by Prof. Dr. Vlad Ratziu.
News and events related to project implementation.
- First stage will end on December 2012.
- Future events: to be announced.